Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
81 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014', provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuro Endocrine (Carcinoid) Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuro Endocrine (Carcinoid) Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neuro Endocrine (Carcinoid) Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neuro Endocrine (Carcinoid) Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Neuro Endocrine (Carcinoid) Carcinoma Overview 7 Therapeutics Development 8 Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Overview 8 Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis 9 Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Development by Companies 10 Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics under Investigation by Universities/Institutes 12 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Neuro Endocrine (Carcinoid) Carcinoma - Products under Development by Companies 16 Neuro Endocrine (Carcinoid) Carcinoma - Products under Investigation by Universities/Institutes 17 Neuro Endocrine (Carcinoid) Carcinoma - Companies Involved in Therapeutics Development 18 F. Hoffmann-La Roche Ltd. 18 Amgen Inc. 19 Ipsen S.A. 20 Novartis AG 21 Lexicon Pharmaceuticals, Inc. 22 Jiangsu Hengrui Medicine Co., Ltd. 23 Camurus AB 24 Vascular Biogenics Ltd. 25 Advanced Accelerator Applications 26 Foresee Pharmaceuticals, LLC 27 Neuro Endocrine (Carcinoid) Carcinoma - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 32 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 telotristat etiprate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 bevacizumab - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Lutathera - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 pasireotide LAR - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ganitumab - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 octreotide acetate - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 SHR-1020 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 VB-111 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 FP-002 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Peptides for Oncology - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BIM-23A758 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Neuro Endocrine (Carcinoid) Carcinoma - Recent Pipeline Updates 60 Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects 70 Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products 71 Neuro Endocrine (Carcinoid) Carcinoma - Product Development Milestones 72 Featured News & Press Releases 72 Oct 16, 2013: AAA reaches halfway recruitment milestone of cancer patients in Lutathera Pivotal Phase III trial 72 Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome 72 Jun 07, 2013: Cedars-Sinai Launches Phase III Clinical Trial Of Lutathera For Metastatic Carcinoid Cancer Patients 73 Oct 12, 2012: Lexicon Pharma Announces Positive Phase II Trial Results Of Telotristat Etiprate In Carcinoid Syndrome 74 Oct 12, 2012: Lexicon Pharma Initiates Phase III Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome 75 Mar 20, 2012: Lexicon's Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment 76 Oct 22, 2011: Lexicon To Present Data From Phase II Clinical Studies Of Telotristat Etiprate At NANETS In Minneapolis, US 77 Aug 09, 2011: Lexicon Announces Positive Results From Phase II Trial Of Telotristat Etiprate In Carcinoid Syndrome 77 Dec 16, 2010: Advanced Accelerator Applications Receives GMP Approval To Manufacture Lutate For Treatment Of Neuroendocrine Tumors 78 Dec 02, 2010: Pfizer Receives European Approval For SUTENT For New Indication In Progressive Pancreatic Neuroendocrine Tumors 79 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 81 Disclaimer 81
List of Tables Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H2 2014 8 Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 18 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Amgen Inc., H2 2014 19 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Ipsen S.A., H2 2014 20 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Novartis AG, H2 2014 21 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 22 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 23 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Camurus AB, H2 2014 24 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2014 25 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Advanced Accelerator Applications, H2 2014 26 Neuro Endocrine (Carcinoid) Carcinoma - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Number of Products by Stage and Target, H2 2014 31 Number of Products by Stage and Mechanism of Action, H2 2014 34 Number of Products by Stage and Route of Administration, H2 2014 36 Number of Products by Stage and Molecule Type, H2 2014 38 Neuro Endocrine (Carcinoid) Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 60 Neuro Endocrine (Carcinoid) Carcinoma - Dormant Projects, H2 2014 70 Neuro Endocrine (Carcinoid) Carcinoma - Discontinued Products, H2 2014 71
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
